<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Journal of Inflammation - Latest articles</title>
		<link>http://www.journal-inflammation.com</link>
		<description>The latest articles from Journal of Inflammation (ISSN 1476-9255) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/5/1/5"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/5/1/4"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/5/1/3"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/5/1/2"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/5/1/1"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/4/1/24"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/4/1/23"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/4/1/22"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/4/1/21"/>			    
            
				    <rdf:li rdf:resource="http://www.journal-inflammation.com/content/4/1/20"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.journal-inflammation.com/content/5/1/5">
            
            <title>Proinflammatory role of amphiregulin, an epidermal growth factor family member whose expression is augmented in rheumatoid arthritis patients</title>
			<description>Background:
The epidermal growth factor (EGF) and EGF receptor (EGFR) families play important roles in the hyperplastic growth of several tissues as well as tumor growth.  Since synovial hyperplasia in rheumatoid arthritis (RA) resembles a tumor, involvement of the EGF/EGFR families in RA pathology has been implied.  Although several reports have suggested that ErbB2 is the most important member of the EGFR family for the synovitis in RA, it remains unclear which members of the EGF family are involved.  To clarify the EGF-like growth factors involved in the pathology of RA, we investigated the expression levels of seven major EGF-like growth factors in RA patients compared with those in osteoarthritis (OA) patients and healthy control subjects.
Methods:
The expression levels of seven EGF-like growth factors and four EGFR-like receptors were measured in mononuclear cells isolated from bone marrow and venous blood, as well as in synovial tissues, using quantitative RT-PCR.  Further evidence of gene expression was obtained by ELISAs.  The proinflammatory roles were assessed by the growth-promoting and cytokine-inducing effects of the corresponding recombinant proteins on cultured fibroblast-like synoviocytes (FLS).
Results:
Among the seven EGF-like ligands examined, only amphiregulin (AREG) was expressed at higher levels in all three RA tissues tested compared with the levels in OA tissues.  The AREG protein concentration in RA synovial fluid was also higher than that in OA synovial fluid.  Furthermore, recombinant human AREG stimulated FLS to proliferate and produce several proinflammatory cytokines, including angiogenic cytokines such as interleukin-8 and vascular endothelial growth factor (VEGF), in a dose-dependent manner.  The VEGF mRNA levels in RA synovia and VEGF protein concentrations in RA synovial fluid were significantly higher than those in the corresponding OA samples and highly correlated with the levels of AREG.
Conclusions:
The present findings suggest that AREG functions to stimulate synovial cells and that elevated levels of AREG may be involved in the pathogenesis of RA. </description>
			<link>http://www.journal-inflammation.com/content/5/1/5</link>
			
			 	<dc:creator>Shoji Yamane, Satoru Ishida, Yukie Hanamoto, Ken-ichi Kumagai, Riako Masuda, Konagi Tanaka, Noriyuki Shiobara, Noriko Yamane, Toshihito Mori, Takuo Juji, Naoshi Fukui, Tsunetoshi Itoh, Takahiro Ochi and Ryuji Suzuki</dc:creator>
			
			<dc:source>Journal of Inflammation 2008, 5:5</dc:source>
			<dc:date>2008-04-27</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-5-5</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/5/1/4">
            
            <title>Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription</title>
			<description>Background:
LMP-420 is a boronic acid-containing purine nucleoside analogue that transcriptionally inhibits TNF production but is non-cytotoxic to TNF-producing cells.
Methods:
This study investigated the efficacy of LMP-420 as an anti-inflammatory agent in acute and chronic colitis induced by oral administration of dextran sulfate sodium (DSS) to mice and in chronic colitis following piroxicam administration to IL-10-deficient mice. The severity of colon inflammation was assessed histologically. TNF levels were measured by enzyme immunoassay.
Results:
Administration of DSS for 7 days resulted in severe acute colitis that was associated with a marked increase in stool and colon tissue TNF levels. Initiation of therapy with intraperitoneal (i.p.) LMP-420 on day 4 of DSS exposure decreased colonic TNF to near normal levels on day 7. However, neither i.p. nor oral treatment with LMP-420 affected the development or severity of acute DSS colitis. Initiation of LMP-420 therapy after 3 cycles of DSS administration to establish chronic colitis also had no effect on the severity of chronic colitis. Analysis of colonic TNF combined with longitudinal analysis of TNF and TNF receptor (TNF-RII) levels in stool during the development of chronic DSS colitis demonstrated that the initially elevated colonic TNF levels returned to normal despite intense on-going inflammation in mice with chronic colitis. RAG-2-/- mice deficient in T and B cells also developed severe ongoing colitis in response to 3 cycles of DSS, but showed marked differences vs. wild type mice in stool TNF and TNF-RII in response to DSS exposure. Systemic and oral LMP-420 treatment for 16 days decreased colonic TNF levels in IL-10-deficient mice with chronic colitis, with a trend to decreased histologic inflammation for oral LMP-420.
Conclusion:
These studies demonstrate that short-term treatment with a transcriptional inhibitor of TNF production can decrease systemic and local colonic levels of TNF but may not decrease the histologic severity of colitis. Longer term studies using colitis models that are more dependent on TNF elevation should be performed to more accurately assess the potential of LMP-420 for therapy of inflammatory bowel disease.</description>
			<link>http://www.journal-inflammation.com/content/5/1/4</link>
			
			 	<dc:creator>Laura P Hale and George Cianciolo</dc:creator>
			
			<dc:source>Journal of Inflammation 2008, 5:4</dc:source>
			<dc:date>2008-03-10</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-5-4</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/5/1/3">
            
            <title>Inhibition of oncogene-induced inflammatory chemokines using a farnesyltransferase inhibitor</title>
			<description>Background:
Farnesyltransferase inhibitors (FTI) are small molecule agents originally formulated to inhibit the oncogenic functions of Ras. Although subsequent analysis of FTI activity revealed wider effects on other pathways, the drug has been demonstrated to reduce Ras signaling by direct measurements. The purpose of the current study was to determine if FTI could be used to inhibit the inflammatory activities of a known Ras-activating human oncoprotein, RET/PTC3. RET/PTC3 is a fusion oncoprotein expressed in the thyroid epithelium of patients afflicted with thyroid autoimmune disease and/or differentiated thyroid carcinoma. Previous studies have demonstrated that RET/PTC3 signals through Ras and can provoke nuclear translocation of NF&#954;B and the downstream release of pro-inflammatory mediators from thyroid follicular cells in vitro and in vivo, making it an ideal target for studies using FTI.
Methods:
For the studies described here, an in vitro assay was developed to measure FTI inhibition of RET/PTC3 pro-inflammatory effects. Rat thyrocytes transfected with RET/PTC3 or vector control cDNA were co-cultured with FTI and examined for inhibition of chemokine expression and secretion measured by RT-PCR and ELISA. Immunoblot analysis was used to confirm the level at which FTI acts on RET/PTC3-expressing cells, and Annexin V/PI staining of cells was used to assess cell death in RET/PTC3-expressing cells co-cultured with FTI.
Results:
These analyses revealed significant mRNA and protein inhibition of chemokines Ccl2 and Cxcl1 with nanomolar doses of FTI. Neither RET/PTC3 protein expression nor apoptosis were affected at any dose of FTI investigated.
Conclusion:
These data suggest that FTI may be applied as an effective inhibitor for RET/PTC3-oncogene induced pro-inflammatory mediators.</description>
			<link>http://www.journal-inflammation.com/content/5/1/3</link>
			
			 	<dc:creator>Katharine C DeGeorge, Brent R DeGeorge, James S Testa and Jay L Rothstein</dc:creator>
			
			<dc:source>Journal of Inflammation 2008, 5:3</dc:source>
			<dc:date>2008-02-27</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-5-3</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-27</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/5/1/2">
            
            <title>Does CD4+CD25+foxp3+ cell (Treg) and IL-10 profile determine susceptibility to immune reconstitution inflammatory syndrome (IRIS) in HIV disease?</title>
			<description>HIV-specific T-lymphocyte responses that underlie IRIS are incomplete and largely remain hypothetical. Of the several mechanisms presented by the host to control host immunological damage, Treg cells are believed to play a critical role. Using the available experimental evidence, it is proposed that enormous synthesis of conventional FoxP3- Th cells (responsive) often renders subjects inherently vulnerable to IRIS, whereas that of natural FoxP3+ Treg cell synthesis predominate among subjects that may not progress to IRIS. We also propose that IRIS non-developers generate precursor T-cells with a high avidity to generate CD4+CD25+FoxP3+ Tregs whereas IRIS developers generate T-cells of intermediate avidity yielding Th0 cells and effector T-cells to mediate the generation of proinflammatory cytokines in response to cell-signaling factors (IL-2, IL-6 etc.). Researchers have shown that IL-10 Tregs (along with TGF-&#946;, a known anti-inflammatory cytokine) limit immune responses against microbial antigens in addition to effectively controlling HIV replication, the prime objective of HAART. Although certain technical limitations are described herein, we advocate measures to test the role of Tregs in IRIS.</description>
			<link>http://www.journal-inflammation.com/content/5/1/2</link>
			
			 	<dc:creator>Esaki Muthu Shankar, Ramachandran Vignesh, Vijayakumar Velu, Kailapuri G Murugavel, Ramalingam Sekar, Pachamuthu Balakrishnan, Charmaine AC Lloyd, Shanmugam Saravanan, Suniti Solomon and Nagalingeswaran Kumarasamy</dc:creator>
			
			<dc:source>Journal of Inflammation 2008, 5:2</dc:source>
			<dc:date>2008-02-18</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-5-2</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>2</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/5/1/1">
            
            <title>Topical anti-inflammatory activity of Polygonum cuspidatum extract in the TPA model of mouse ear inflammation</title>
			<description>Background:
This study tested the ability of a characterized extract of Polygonum cuspidatum (PCE) to inhibit mouse ear inflammation in response to topical application of 12-O-tetradecanoylphorbol-13-acetate (TPA).
Methods:
A 50% (wt:vol) ethanolic solution of commercial 200:1 PCE was applied to both ears of female Swiss mice (n = 8) at 0.075, 0.15, 0.3, 1.25 and 2.5 mg/ear 30 min after TPA administration (2 &#956;g/ear). For comparison, 3 other groups were treated with TPA and either 1) the vehicle (50% ethanol) alone, 2) indomethacin (0.5 mg/ear), or 3) trans-resveratrol (0.62 mg/ear). Ear thickness was measured before TPA and at 4 and 24 h post-TPA administration to assess ear edema. Ear punch biopsies were collected at 24 h and weighed as a second index of edema. Myeloperoxidase activity was measured in each ear punch biopsy to assess neutrophil infiltration.
Results:
PCE treatment at all doses significantly reduced ear edema compared to the TPA control. The PCE response was dose-dependent and 2.5 mg PCE significantly inhibited all markers of inflammation to a greater extent than indomethacin (0.5 mg). MPO activity was inhibited at PCE doses &#8805; 1.25 mg/ear. Trans-resveratrol inhibited inflammation at comparable doses.
Conclusion:
PCE inhibits development of edema and neutrophil infiltration in the TPA-treated mouse ear model of topical inflammation.</description>
			<link>http://www.journal-inflammation.com/content/5/1/1</link>
			
			 	<dc:creator>Eve E Bralley, Phillip Greenspan, James L Hargrove, Louise Wicker and Diane K Hartle</dc:creator>
			
			<dc:source>Journal of Inflammation 2008, 5:1</dc:source>
			<dc:date>2008-02-08</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-5-1</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>5</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-08</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/4/1/24">
            
            <title>Detection of inflammatory bowel disease by proton magnetic resonance spectroscopy (1H MRS) using an animal model</title>
			<description>Background:
The aim of this study was to analyze the potential of proton magnetic resonance spectroscopy (1H MRS) in diagnosing early inflammatory bowel disease (IBD).
Methods:
Thirty male Sprague Dawley rats were fed 2% carrageenan in their diet for either 1 or 2 weeks. 1H MRS was performed ex-vivo on colonic mucosal samples (n = 123) and the spectra were analyzed by a multivariate method of analysis. The results of the multivariate analysis were correlated with histological analysis performed using H &amp; E stain for the presence of inflammation in the samples from each group.
Results:
Multivariate analysis classified the samples in their respective groups with an accuracy of 82%. Our region selection algorithm identified four regions in the spectra as being discriminatory. The metabolites assigned to these regions include creatine, phosphatidylcholine, the -CH2HC= group in fatty acyl chain, and the glycerol backbone of lipids. The differences in concentration of these metabolites in each group offer insight into the biochemical changes occurring during IBD and confer diagnostic potential to 1H MRS as a tool to study colonic inflammation in conjunction with biopsy.
Conclusion:
1H MRS is a sensitive tool to detect early colonic inflammation in an animal model of IBD.</description>
			<link>http://www.journal-inflammation.com/content/4/1/24</link>
			
			 	<dc:creator>Sonal Varma, Ranjana Bird, Michael Eskin, Brion Dolenko, Jayadev Raju and Tedros Bezabeh</dc:creator>
			
			<dc:source>Journal of Inflammation 2007, 4:24</dc:source>
			<dc:date>2007-11-26</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-4-24</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>24</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/4/1/23">
            
            <title>Modulation of LPS stimulated NF-kappaB mediated Nitric Oxide production by PKC&#949; and JAK2 in RAW macrophages</title>
			<description>Background:
Nuclear factor kappa B (NF-&#954;B) has been shown to play an important role in regulating the expression of many genes involved in cell survival, immunity and in the inflammatory processes. NF-&#954;B activation upregulates inducible nitric oxide synthase leading to enhanced nitric oxide production during an inflammatory response. NF-&#954;B activation is regulated by distinct kinase pathways independent of inhibitor of &#954;B kinase (IKK). Here, we examine the role of protein kinase C isoforms and janus activated kinase 2 (JAK2) activation in NF-&#954;B activation and LPS-stimulated NO production.
Methods:
Murine RAW 264.7 macrophages were treated with lipopolysaccharide (LPS), Phorbol 12-myristate 13-acetate (PMA) and a combination of LPS and PMA in the presence or absence of various inhibitors of PKC isoforms and JAK2. Nuclear translocation of the NF-&#954;B p65 subunit, was assessed by Western blot analysis whilst NO levels were assessed by Greiss assay.
Results:
LPS-stimulated NO production was attenuated by PMA whilst PMA alone did not affect NO release. These effects were associated with changes in p65 nuclear translocation. The PKC&#945;, &#946;, &#947;, &#948; and &#950; inhibitor G&#246; 6983 (Go) had no effect on LPS-induced NO release. In contrast, Bisindolymalemide I (Bis), a PKC &#945;, &#946;I, &#946;II, &#947;, &#948; and &#949; isoform inhibitors completely inhibited LPS-stimulated NO production without affecting p65 nuclear translocation. Furthermore, a partial inhibitory effect on LPS-induced NO release was seen with the JAK2 inhibitor AG-490 and the p38 MAPK inhibitor SB 203850.
Conclusion:
The results further define the role of NF-&#954;B in LPS stimulated NO production in RAW macrophages. The data support a function for PKC&#949;, JAK2 and p38 MAPK in NF-&#954;B activation following p65 nuclear import.</description>
			<link>http://www.journal-inflammation.com/content/4/1/23</link>
			
			 	<dc:creator>Edward Jones, Ian M Adcock, Bushra Y Ahmed and Neville A Punchard</dc:creator>
			
			<dc:source>Journal of Inflammation 2007, 4:23</dc:source>
			<dc:date>2007-11-24</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-4-23</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>23</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-24</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/4/1/22">
            
            <title>Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet</title>
			<description>Background:
It was hypothesized that a pro-atherogenic, high saturated fat and cholesterol diet (HCD) would increase the inflammatory response to E. coli endotoxin (LPS) and increase its concentration in plasma after administration to mice.
Methods:
C57Bl/6 mice were fed a HCD or a control diet (CD) for 4 weeks, and then treated with saline, 0.5, 1 or 2 mg LPS/kg, ip. Liver injury (alanine:2-oxoglutarate aminotransferase and aspartate aminotransferase, collagen staining), circulating cytokines (tumor necrosis factor-&#945;, interleukin-6 and interferon-&#947;), factors that can bind LPS (serum amyloid A, apolipoprotein A1, LPS binding protein, and CD14), and plasma levels of LPS were measured. The hepatic response was assessed by measuring vascular cell adhesion molecule (VCAM)-1, inducible nitric oxide synthase (iNOS) and signal transducer and activator of transcription-1 proteins, and VCAM-1 and iNOS mRNAs. Hepatic mRNA encoding the LPS receptor, Toll like receptor 4, was also determined.
Results:
Two mg LPS/kg killed 100% of mice fed HCD within 5 d, while no mice fed CD died. All mice treated with 0 to 1 mg LPS/kg survived 24 h. HCD increased plasma alanine:2-oxoglutarate aminotransferase and aspartate aminotransferase, and the enzymes were increased more by LPS in HCD than CD mice. Induction of plasma tumor necrosis factor-&#945;, interleukin-6, and interferon-&#947; by LPS was greater with HCD than CD. Hepatic VCAM-1 and iNOS protein and mRNA were induced by LPS more in mice fed HCD than CD. Tyrosine phosphorylation of signal transducer and activator of transcription-1 caused by LPS was prolonged in HCD compared with CD mice. Despite the hepatic effects of HCD, diet had no effect on the LPS plasma concentration-time profile. HCD alone did not affect circulating levels of plasma apolipoprotein A1 or LPS binding protein. However, plasma concentrations of serum amyloid A and CD14, and hepatic toll-like receptor-4 mRNA were increased in mice fed HCD.
Conclusion:
HCD increased the sensitivity of mice to LPS without affecting its plasma level. Although increased serum amyloid A and CD14 in the circulation may inhibit LPS actions, their overexpression, along with hepatic toll-like receptor-4 or other factors, may contribute to the heightened sensitivity to LPS.</description>
			<link>http://www.journal-inflammation.com/content/4/1/22</link>
			
			 	<dc:creator>Hong Huang, Tongzheng Liu, Jane L Rose, Rachel L Stevens and Dale G Hoyt</dc:creator>
			
			<dc:source>Journal of Inflammation 2007, 4:22</dc:source>
			<dc:date>2007-11-12</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-4-22</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>22</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/4/1/21">
            
            <title>Inhibition of neutrophil activity improves cardiac function after cardiopulmonary bypass</title>
			<description>Background:
The arterial in line application of the leukocyte inhibition module (LIM) in the cardiopulmonary bypass (CPB) limits overshooting leukocyte activity during cardiac surgery. We studied in a porcine model whether LIM may have beneficial effects on cardiac function after CPB.
Methods:
German landrace pigs underwent CPB (60 min myocardial ischemia; 30 min reperfusion) without (group I; n = 6) or with LIM (group II; n = 6). The cardiac indices (CI) and cardiac function were analyzed pre and post CPB with a Swan-Ganz catheter and the cardiac function analyzer. Neutrophil labeling with technetium, scintigraphy, and histological analyses were done to track activated neutrophils within the organs.
Results:
LIM prevented CPB-associated increase of neutrophil counts in peripheral blood. In group I, the CI significantly declined post CPB (post: 3.26 &#177; 0.31; pre: 4.05 &#177; 0.45 l/min/m2; p &lt; 0.01). In group II, the CI was only slightly reduced (post: 3.86 &#177; 0.49; pre 4.21 &#177; 1.32 l/min/m2; p = 0.23). Post CPB, the intergroup difference showed significantly higher CI values in the LIM group (p &lt; 0.05) which was in conjunction with higher pre-load independent endsystolic pressure volume relationship (ESPVR) values (group I: 1.57 &#177; 0.18; group II: 1.93 &#177; 0.16; p &lt; 0.001). Moreover, the systemic vascular resistance and pulmonary vascular resistance were lower in the LIM group. LIM appeared to accelerate the sequestration of hyperactivated neutrophils in the spleen and to reduce neutrophil infiltration of heart and lung.
Conclusion:
Our data provides strong evidence that LIM improves perioperative hemodynamics and cardiac function after CPB by limiting neutrophil activity and inducing accelerated sequestration of neutrophils in the spleen.</description>
			<link>http://www.journal-inflammation.com/content/4/1/21</link>
			
			 	<dc:creator>Ulf Abdel-Rahman, Stefan Margraf, Tayfun Aybek, Tim L&#246;gters, Jos&#233; Bitu-Moreno, Ieda Francischetti, Tilmann Kranert, Frank Gr&#252;nwald, Joachim Windolf, Anton Moritz and Martin Scholz</dc:creator>
			
			<dc:source>Journal of Inflammation 2007, 4:21</dc:source>
			<dc:date>2007-10-10</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-4-21</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>21</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-10-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.journal-inflammation.com/content/4/1/20">
            
            <title>Induction of cystine/glutamate transporter in bacterial lipopolysaccharide induced endotoxemia in mice</title>
			<description>Background:
Cystine/glutamate transporter, system xc-, contributes to the maintenance of intracellular glutathione levels and the redox balance in the extracellular space. The main component of the transporter, xCT, is known to be strongly induced by various stimuli like oxidative stress in mammalian cultured cells. We examined the expression of xCT mRNA in vivo in the experimental endotoxemia.
Methods:
Northern blot analysis and in situ hybridization were used to investigate the expression of xCT mRNA in the tissues of the mice exposed to bacterial lipopolysaccharide (LPS).
Results:
Northern blot analysis revealed that xCT mRNA was constitutively expressed in the brain, thymus, and spleen, and that the expression of xCT mRNA was strongly up-regulated in thymus and spleen by the administration of a sublethal dose of LPS. In addition to brain, thymus, and spleen, xCT mRNA was detected also in the bronchiolar epithelium of the lung by the administration of the lethal dose of LPS.
Conclusion:
xCT is induced in some specific tissues by the administration of LPS. The results suggest that cystine/glutamate transporter plays an important role under the inflammatory conditions.</description>
			<link>http://www.journal-inflammation.com/content/4/1/20</link>
			
			 	<dc:creator>Kumiko Taguchi, Michiko Tamba, Shiro Bannai and Hideyo Sato</dc:creator>
			
			<dc:source>Journal of Inflammation 2007, 4:20</dc:source>
			<dc:date>2007-09-26</dc:date>
			<dc:identifier>doi:10.1186/1476-9255-4-20</dc:identifier>
			
			
							
					<prism:publicationName>Journal of Inflammation</prism:publicationName>
					
			
							
					<prism:issn>1476-9255</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>20</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-09-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
